Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sunitinib in the Treatment of Thyroid Cancer.
Ferrari SM, Centanni M, Virili C, Miccoli M, Ferrari P, Ruffilli I, Ragusa F, Antonelli A, Fallahi P. Ferrari SM, et al. Among authors: ragusa f. Curr Med Chem. 2019;26(6):963-972. doi: 10.2174/0929867324666171006165942. Curr Med Chem. 2019. PMID: 28990511 Review.
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P. Ferrari SM, et al. Among authors: ragusa f. Oncol Rep. 2018 May;39(5):2225-2234. doi: 10.3892/or.2018.6306. Epub 2018 Mar 8. Oncol Rep. 2018. PMID: 29517103
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.
Ferrari SM, Bocci G, Di Desidero T, Ruffilli I, Elia G, Ragusa F, Fioravanti A, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P. Ferrari SM, et al. Among authors: ragusa f. Oncol Rep. 2018 May;39(5):2306-2314. doi: 10.3892/or.2018.6305. Epub 2018 Mar 8. Oncol Rep. 2018. PMID: 29517106
Novel treatment options for anaplastic thyroid cancer.
Fallahi P, Ruffilli I, Elia G, Ragusa F, Ulisse S, Baldini E, Miccoli M, Materazzi G, Antonelli A, Ferrari SM. Fallahi P, et al. Among authors: ragusa f. Expert Rev Endocrinol Metab. 2017 Jul;12(4):279-288. doi: 10.1080/17446651.2017.1340155. Epub 2017 Jun 15. Expert Rev Endocrinol Metab. 2017. PMID: 30058884
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A. Fallahi P, et al. Among authors: ragusa f. Semin Cancer Biol. 2022 Feb;79:180-196. doi: 10.1016/j.semcancer.2020.11.013. Epub 2020 Nov 26. Semin Cancer Biol. 2022. PMID: 33249201 Review.
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer.
Ferrari SM, Elia G, Ragusa F, Paparo SR, Mazzi V, Miccoli M, Galdiero MR, Varricchi G, Foddis R, Guglielmi G, Spinelli C, La Motta C, Benvenga S, Antonelli A, Fallahi P. Ferrari SM, et al. Among authors: ragusa f. Expert Opin Investig Drugs. 2021 Sep;30(9):913-921. doi: 10.1080/13543784.2021.1972971. Epub 2021 Sep 6. Expert Opin Investig Drugs. 2021. PMID: 34428101 Review.
351 results